Journals / Medical Records / 2021 / Cilt: 3 Sayı: 2

The Evaluation of Dentists’ Awareness and Knowledge in Turkey Regarding Bisphosphonates

Türkiye’de Diş Hekimlerinin Bifosfonatlar Konusundaki Farkındalık Ve Bilgilerinin Değerlendirilmesi

Pages
130–137
Publication Date
2021-05-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Greater efforts are required to increase education and knowledge of MRONJ and BPs among dental practitioners.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Bisphosphonates (BPs) are inorganic pyrophosphate analogs used for the treatment of various diseases.
📊
Key Findings & Data:This study aimed to evaluate the knowledge and attitudes of general dental practitioners (GDP), specialist trainees (ST), and specialists (S) in Turkey toward medication-related osteonecrosis of the jaw (MRONJ) and to optimize future training programs in this field.Materials and Methods: A self-report questionnaire consisting of 7 questions about demographic data, knowledge about BPs, MRONJ and treatment modalities was prepared and send to the members of Turkish Dental Association via email.
💡
Conclusion & Impact:Greater efforts are required to increase education and knowledge of MRONJ and BPs among dental practitioners.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:İlaca bağlı çene osteonekrozları · bisfosfonatlar · diş hekimi

Abstract

Aim: Bisphosphonates (BPs) are inorganic pyrophosphate analogs used for the treatment of various diseases. This study aimed to evaluate the knowledge and attitudes of general dental practitioners (GDP), specialist trainees (ST), and specialists (S) in Turkey toward medication-related osteonecrosis of the jaw (MRONJ) and to optimize future training programs in this field.Materials and Methods: A self-report questionnaire consisting of 7 questions about demographic data, knowledge about BPs, MRONJ and treatment modalities was prepared and send to the members of Turkish Dental Association via email. Results: A total of 209 participants were included in this survey. The mean age of the ST group was significantly lower than the mean ages of the GDP and S groups (P= 0.003, P= 0.038). GDP are less likely to think of BPs administration and radiotherapy treatment than S or ST upon observation of an exposed bone in the head-and-neck region (P=0.048, P=0.008). In comparison to the S and ST groups, the GDP group displayed less knowledge regarding the radiological and intraoral examination of patients undergoing BP therapy (P= 0.034).Conclusion: The increasing awareness of dentists about usage and side effects of BPs is important for preventing MRONJ. The GDP group displayed significantly less knowledge regarding the radiological and intraoral examinations of patients undergoing BP therapy. Greater efforts are required to increase education and knowledge of MRONJ and BPs among dental practitioners.

Özet

Amaç: Bisfosfonatlar çeşitli hastalıkların tedavisinde kullanılan inorganik pirofosfat analoglarıdır. Bu çalışma uzman olmayan diş hekimlerinin, uzmanlık öğrencilerinin ve uzmanların ilaca bağlı gelişen çene osteonekrozuna yönelik bilgi ve tutumlarını değerlendirmenin yanında, gelecekteki eğitim programlarını optimize etmeyi amaçlamıştır.Materyal ve Metot: Çalışmaya 209 katılımcı dahil edilmiştir. Türk Dişhekimleri Birliği’nin desteğiyle bir anket hazırlanmış ve üyeler arasında e-posta ile paylaşılmıştır. Katılımcıların demografik bilgiler, ilaca bağlı çene osteonekrozları, bisfosfonatlar ve tedavi yaklaşımları ile ilgili 7 sorudan oluşan anketi yanıtlamaları istenmiştir. Bu anket sorularına hekimlerin verdiği cevaplar sayı ve yüzde ile tanımlanmıştır.Bulgular: Ankete katılan uzmanlık öğrencilerinin ortalama yaşı, uzman olmayan diş hekimleri ve uzmanlardan anlamlı olarak düşük bulunmuştur (P = 0.003, P = 0.038). Uzman olmayan diş hekimleri, baş-boyun bölgesinde gözlemlenen ekspoze kemiğin bisfosfonat tedavisi ya da radyoterapiye bağlı olabilme ihtimalini diğer gruplara göre daha az değerlendirmiştir (P=0.048, P=0.008). Uzman ve uzmanlık öğrencilerine kıyasla uzman olmayan diş hekimleri, bisfosfonat kullanan hastaların radyolojik ve ağız içi bulguları hakkında daha az bilgi sahibi olduğunu belirtmiştir (P = 0.034).Sonuç: Diş hekimlerinin bisfosfonatların kullanımı ve yan etkileri konusunda artan farkındalığı MRONJ’un önlenmesi için önemlidir. Diş hekimleri arasında MRONJ ve bisfosfonatlar ile ilgili bilincin artırılması için daha fazla çaba gösterilmesi ve hedef kitleye yönelik eğitim planları oluşturulması gerekmektedir.

🔖

Cite This Article

KASAPOĞLU, M. B., ÇANKAYA, B., KÖSE, T., KÖSE, O. D., ARSAN, B., ÇEBİ, A. T., ERDEM, M. (2021). The Evaluation of Dentists’ Awareness and Knowledge in Turkey Regarding Bisphosphonates. Medical Records, Cilt: 3 Sayı: 2, 130–137. https://ajindex.com/articles/910159

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. References 1. Sigua-Rodriguez EA, da Costa Ribeiro R, de Brito AC, Alvarez-Pinzon N, de Albergaria-Barbosa JR. Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent 2014;2014:192320. 2. Masson DR, O’Callaghan E, Seager M. The knowledge and attitudes of North Wales healthcare professionals to bisphosphonate associated osteochemonecrosis of the jaws. JDOH 2009;10:175-183. 3. Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S. Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg 2011;40: 277-282. 4. Liu J, Huang W, Zhou R, Jia S, Tang W, Luo Y, Zhang J. Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: a meta-analysis. Medicine (Baltimore) 2015;94:1-4. 5. Tanna N., Steel C., Stagnell S., Bailey E. (2017). Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. BDJ 2017;222:121-125. 6. Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A, Semper-Hogg W. Update MRONJ and perspectives of its treatment. Journal of Somatology, Oral and Maxillofacial surgery, 2017;118:232-235. 7. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaw associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-1107. 8. Pazdur R. Postmarketing safety review: Bisphosphonates. Food and Drug Administration, Office of Drug Safety. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095b2_03_02-fda-tab1.doc; Accessed January 2017. 9. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 2014;72:1938-1956. 10. Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev 2015;41:455-464. 11. Walter C, Laux C, Sagheb K. Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig 2014;18:385-390. 12. Fantasia JE. Bisphosphonates—what the dentist needs to know: practical considerations. J Oral Maxillofac Surg 2009;67:53-60. 13. Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J 2011;32:830-835. 14. Hong JW, Nam W, Cha IH, et al. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporos Int 2010;21:847-853. 15. Benin